Brain, Vol. 113, No. 5, 1539-1552, 1990
© 1990 Guarantors of Brain
research-article |
THE RELATIONSHIP BETWEEN LOCOMOTOR DISABILITY, AUTONOMIC DYSFUNCTION, AND THE INTEGRITY OF THE STRIATAL DOPAMINERGIC SYSTEM IN PATIENTS WITH MULTIPLE SYSTEM ATROPHY, PURE AUTONOMIC FAILURE, AND PARKINSON'S DISEASE, STUDIED WITH PET
1MRC Cyclotron Unit, Hammersmith Hospital, Queen Square London, UK 2National Hospital for Nervous Diseases, Queen Square London, UK
Correspondence to:
Correspondence to: Dr D. J. Brooks, MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
18F-dopa and S-11C-nomifensine (NMF) are position emitting tracers whose caudate and putamen uptake reflects striatal dopamine stroage capacity and the integrity of dopamine reuptake sites, respectively. Using these two tracers, the integrity of the presynaptic striatal dopaminergic system has been studied with position emission tomography (PET) in 10 subjects with multiple system atrophy (MSA, Shy-Drager syndrome) who had an akinetic-rigid syndrome that was poorly responsive to L-dopa, autonomic failure, and cerebellar alaxia. PET findings for the 10 MSA patients were compared with those for 13 age-matched controls, 8 subjects with L-dopa responsive Parkinson's disease (PD), and 7 subjects with pure autonomic failure (PAF).
Influx constants, Ki, reflecting specific 18F-dopa uptake into strialal tissue, were severely reduced in the putamen and caudate of the 10 MSA subjects [mean putamen Ki 0.005 min–1 MSA vs 0.013 min–1 controls; mean caudate Ki 0.007 min–1 MSA vs 0.013 min–1 controls]. Reduction of putamen, but not caudate, 18F-dopa uptake correlated with severity and duration of locomotor disability. Eight patients with PD, and a similar degree and duration of locomotor disability to the patients with MSA, demonstrated equal impairment of mean putamen 18F-dopa uptake, but significant preservation of mean caudate function. The 7 PAF patients had normal mean levels of putamen and caudate 18F-dopa uptake, although 1 individual PAF patient had significantly impaired striatal function.
The MSA and PD groups of subjects both showed significantly reduced levels of specific strialal S-11C-NMF binding, again caudate function being relatively preserved in PD. It is concluded that in both MSA and PD there is a parallel decline of strialal dopamine storage capacity and reuptake site integrity, probably reflecting a loss of nigrostrital nerve terminals. Caudate function is relatively preserved in PD compared with MSA. The majority of PAF patients have an intact nigrostriatal dopaminergic system, suggesting that PAF is a condition distinct from PD and MSA in spite of some pathological similarities. PET is capable of detecting subclinical nigrostriatal involvement in PAF patients when this is present.
Received July 19, 1989. Accepted November 21, 1989.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Suzuki, S. Watanabe, T. Hamaguchi, H. Mine, T. Terui, M. Kanazawa, N. Oohisa, M. Maruyama, T. Yambe, M. Itoh, et al. Brain Activation Associated With Changes in Heart Rate, Heart Rate Variability, and Plasma Catecholamines During Rectal Distention Psychosom Med, July 1, 2009; 71(6): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jokinen, H. Helenius, E. Rauhala, A. Bruck, O. Eskola, and J. O. Rinne Simple Ratio Analysis of 18F-Fluorodopa Uptake in Striatal Subregions Separates Patients with Early Parkinson Disease from Healthy Controls J. Nucl. Med., June 1, 2009; 50(6): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Compta, M. J. Marti, P. Paredes, and E. Tolosa Pure autonomic failure with altered dopamine transporter imaging. Arch Neurol, April 1, 2006; 63(4): 604 - 605. [Full Text] [PDF]
|
|
|
|
 |
|
 A L Cheesman, R A Barker, S J G Lewis, T W Robbins, A M Owen, and D J Brooks Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1204 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. -L. Kuan and R. A. Barker New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181. [Abstract] [PDF]
|
|
|
|
|
|
S. Thobois, M.-J. Ribeiro, E. Lohmann, A. Durr, P. Pollak, O. Rascol, S. Guillouet, E. Chapoy, N. Costes, Y. Agid, et al. Young-Onset Parkinson Disease With and Without Parkin Gene Mutations: A Fluorodopa F 18 Positron Emission Tomography Study Arch Neurol, May 1, 2003; 60(5): 713 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dhawan, Y. Ma, V. Pillai, P. Spetsieris, T. Chaly, A. Belakhlef, C. Margouleff, and D. Eidelberg Comparative Analysis of Striatal FDOPA Uptake in Parkinson's Disease: Ratio Method Versus Graphical Approach J. Nucl. Med., October 1, 2002; 43(10): 1324 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Ribeiro, M. Vidailhet, C. Loc'h, C. Dupel, J. P. Nguyen, M. Ponchant, F. Dolle, M. Peschanski, P. Hantraye, P. Cesaro, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease Arch Neurol, April 1, 2002; 59(4): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Piccini, J. de Yebenez, A. J. Lees, R. Ceravolo, N. Turjanski, P. Pramstaller, and D. J. Brooks Familial Progressive Supranuclear Palsy: Detection of Subclinical Cases Using 18F-Dopa and 18Fluorodeoxyglucose Positron Emission Tomography Arch Neurol, November 1, 2001; 58(11): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kaasinen, E. Nurmi, A. Bruck, O. Eskola, J. Bergman, O. Solin, and J. O. Rinne Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex Brain, June 1, 2001; 124(6): 1125 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. M. Hu, S. J. White, A. H. Herlihy, K. R. Chaudhuri, J. V. Hajnal, and D. J. Brooks A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease Neurology, May 8, 2001; 56(9): 1195 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Stolze, J P Kuhtz-Buschbeck, H Drucke, K Johnk, M Illert, and G Deuschl Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 289 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Broussolle, C. B. Lucking, N. Ginovart, P. Pollak, P. Remy, and A. Durr [18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations Neurology, September 26, 2000; 55(6): 877 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Rinne, R. Portin, H. Ruottinen, E. Nurmi, J. Bergman, M. Haaparanta, and O. Solin Cognitive Impairment and the Brain Dopaminergic System in Parkinson Disease: [18F]Fluorodopa Positron Emission Tomographic Study Arch Neurol, April 1, 2000; 57(4): 470 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Aberg, K. Liewendahl, P. Nikkinen, T. Autti, J. O. Rinne, and P. Santavuori Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms Neurology, March 14, 2000; 54(5): 1069 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O Rinne, H. Ruottinen, J. Bergman, M. Haaparanta, P. Sonninen, and O. Solin Usefulness of a dopamine transporter PET ligand [18F]beta -CFT in assessing disability in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, December 1, 1999; 67(6): 737 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Rakshi, T. Uema, K. Ito, D. L. Bailey, P. K. Morrish, J. Ashburner, A. Dagher, I. H. Jenkins, K. J. Friston, and D. J. Brooks Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study Brain, September 1, 1999; 122(9): 1637 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Ito, P K Morrish, J S Rakshi, T Uema, J Ashburner, D L Bailey, K J Friston, and D J Brooks Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 754 - 758. [Abstract] [Full Text]
|
|
|
|
|
|
N. Turjanski, A. J. Lees, and D. J. Brooks Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies Neurology, March 1, 1999; 52(5): 932 - 932. [Abstract] [Full Text]
|
|
|
|
|
|
P K Morrish, J S Rakshi, D L Bailey, G V Sawle, and D J Brooks Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET J. Neurol. Neurosurg. Psychiatry, March 1, 1998; 64(3): 314 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Holthoff-Detto, J. Kessler, K. Herholz, H. Bonner, U. Pietrzyk, M. Wurker, M. Ghaemi, K. Wienhard, R. Wagner, and W.-D. Heiss Functional Effects of Striatal Dysfunction in Parkinson Disease Arch Neurol, February 1, 1997; 54(2): 145 - 150. [Abstract] [PDF]
|
|
|
|
|
|
G. V. Sawle, E. D. Playford, D. J. Burn, V. J. Cunningham, and D. J. Brooks Separating Parkinson's Disease From Normality: Discriminant Function Analysis of Fluorodopa F 18 Positron Emission Tomography Data Arch Neurol, March 1, 1994; 51(3): 237 - 243. [Abstract] [PDF]
|
|